Cerus Corporation
2550 Stanwell Drive
Concord
California
94520
United States
Tel: 925-288-6000
Website: http://www.cerus.com/
446 articles about Cerus Corporation
-
Cerus Corporation Announces the Inclusion of Pathogen Reduction Technology in the ISBT Working Party Recommendations for the Preparation of COVID-19 Convalescent Plasma
4/2/2020
Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled “ Points to consider in the preparation and transfusion of COVID-19 convalescent plasma .” The document was authored by Dr. Jay Epstein and Dr. Thierry Burnouf, two key opinion leaders in the field of transfusion medicine. “Convalescent plasma h
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
-
Cerus Forms Group to Research Optimal Production of COVID-19 Convalescent Plasma
3/26/2020
Cerus Corporation (Nasdaq: CERS) announced today that it has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the
-
Cerus Corporation Announces Strategic Organizational Changes
3/2/2020
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader
-
Cerus Corporation Announces Record Fourth Quarter and Full Year 2019 Financial Results
2/20/2020
Cerus Corporation announced complete financial results for the fourth quarter and year ended December 31, 2019.
-
U.S. Department of Defense Awards Funding for Study to Evaluate the Use of INTERCEPT Plasma in Traumatic Burn Resuscitation
2/18/2020
Cerus Corporation (Nasdaq: CERS) today announced a collaboration with the National Trauma Institute (NTI) to supply INTERCEPT plasma for use in the Plasma Resuscitation Without Lung Injury (PROpOLIs) clinical study.
-
Cerus Corporation Announces Pricing of Upsized Public Offering of Common Stock
1/29/2020
Cerus Corporation (Nasdaq: CERS) announced today the pricing of a registered underwritten public offering of its common stock for proceeds of approximately $55.0 million, before deducting estimated offering expenses payable by Cerus.
-
Cerus Corporation Announces Public Offering of Common Stock
1/28/2020
Cerus Corporation (Nasdaq: CERS) announced today that it has commenced a registered underwritten public offering of $50.0 million of its common stock
-
Coronavirus Inactivation Reported in Recent INTERCEPT Blood System Publication in Transfusion Medicine
1/23/2020
Cerus Corporation (Nasdaq:CERS) today announced the publication of a study in Transfusion Medicine1 on the inactivation of the MERS (Middle Eastern Respiratory Syndrome) coronavirus in human platelet concentrates using the INTERCEPT Blood System for platelets.
-
French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use
1/21/2020
Cerus Corporation (Nasdaq:CERS) is pleased to announce the recent publication of the 16th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of medicine and other health products.
-
Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2019 Product Revenue
1/13/2020
Company provides 2020 product revenue guidance range of $89 million to $93 million representing growth of approximately 20% to 25% over preliminary 2019 full year results
-
Cerus Corporation Announces New Five-Year INTERCEPT Blood System Agreement With Swiss Transfusion SRC
12/12/2019
Cerus Corporation (Nasdaq:CERS) announced today that it has signed a new five-year commercial contract with Swiss Transfusion SRC, a company of the Swiss Red Cross, for purchase of the INTERCEPT Blood System.
-
Cerus Corporation to Present at the Stifel 2019 Healthcare Conference
11/13/2019
Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m. ET in New York City.
-
Cerus Corporation to Present at the Stephens Nashville Investment Conference
11/8/2019
Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m. CT.
-
Cerus Corporation Announces Third Quarter 2019 Results
10/30/2019
Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2019.
-
Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting
10/18/2019
Cerus Corporation (Nasdaq:CERS) announced today its schedule of key events and presentations at the 2019 AABB Annual Meeting which is taking place in San Antonio, Texas on October 19th through October 22nd.
-
Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion
9/30/2019
Cerus Corporation applauds the publication of the FDA final guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Guidance for Industry.
-
Cerus Corporation to Present at the 2019 Cantor Global Healthcare Conference
9/27/2019
Cerus Corporation announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer will present and provide a corporate update at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019 at 3:00 p.m. ET.
-
Cerus Corporation to Participate in Upcoming Investor Conferences
8/28/2019
Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in two upcoming investor conferences.
-
Cerus Corporation Announces Record Second Quarter 2019 Results
8/1/2019
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2019.